These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30992818)

  • 1. HBV treatment in a patient who will be receiving immunosuppressive therapy.
    Feld JJ
    Clin Liver Dis (Hoboken); 2013 Feb; 2(1):34-37. PubMed ID: 30992818
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis.
    Fang J; Li W; Peng X; Tan Z; Tan M; Zhang C; Wang W; Xu Z; Zhou G
    Int Urol Nephrol; 2017 Mar; 49(3):475-482. PubMed ID: 28032257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of nucleoside analogue prophylactic treatment on HBV activation in HBcAb+ patients undergoing immunosuppressive therapy.
    Liu HL; Zhao Z; Yang H; Liu FF; Liu Q; Luo Q; Yuan Q; Chen LM; Zeng AZ
    J Viral Hepat; 2013 Sep; 20(9):645-9. PubMed ID: 23910649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy.
    Harigai M; Mochida S; Mimura T; Koike T; Miyasaka N
    Mod Rheumatol; 2014 Jan; 24(1):1-7. PubMed ID: 24261752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-core mutants of hepatitis B virus in patients receiving immunosuppressive treatment after orthotopic liver transplantation.
    Protzer U; Goergen B; Hopf U; Neuhaus P; König V; Meyer zum Büschenfelde KH; Gerken G
    J Med Virol; 1996 Oct; 50(2):135-44. PubMed ID: 8915879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies.
    Mochida S; Nakao M; Nakayama N; Uchida Y; Nagoshi S; Ido A; Mimura T; Harigai M; Kaneko H; Kobayashi H; Tsuchida T; Suzuki H; Ura N; Nakamura Y; Bessho M; Dan K; Kusumoto S; Sasaki Y; Fujii H; Suzuki F; Ikeda K; Yamamoto K; Takikawa H; Tsubouchi H; Mizokami M
    J Gastroenterol; 2016 Oct; 51(10):999-1010. PubMed ID: 26831356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal timing of antiviral therapy for patients with malignant tumor who presented with hepatitis B reactivation during chemotherapy and/or immunosuppressive therapy.
    Zou X; Guo L; Gu Y; Yang Z; Huang P; Liu T; Zhao J; Wu G
    J Cancer; 2020; 11(12):3559-3566. PubMed ID: 32284752
    [No Abstract]   [Full Text] [Related]  

  • 9. Prophylaxis of hepatitis B reactivation with immunosuppressive therapy in rheumatic diseases. Orientations for clinical practice.
    Nunes J; Marinho RT; Fonseca JE; Pereira da Silva JA; Velosa J
    Acta Reumatol Port; 2011; 36(2):110-8. PubMed ID: 21841730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy.
    Oketani M; Ido A; Uto H; Tsubouchi H
    Hepatol Res; 2012 Jul; 42(7):627-36. PubMed ID: 22686858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overuse of prophylaxis in HBsAg and/or anti-HBc positive patients after increasing awareness to prevent reactivation in patients receiving immunosuppressive therapies: How rational are our prophylaxis decisions according to the literature?
    Yenilmez E; Cetinkaya RA
    Infez Med; 2019 Sep; 27(3):299-307. PubMed ID: 31545774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014.
    Patel A; Yapali S; Lok AS
    Hepatol Int; 2016 Jan; 10(1):139-46. PubMed ID: 26272106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm].
    Terrier B; Pol S; Thibault V; Gottenberg JE; Cacoub P;
    Rev Med Interne; 2012 Jan; 33(1):4-12. PubMed ID: 21889826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B reactivation in patients receiving targeted therapies.
    Chang CS; Tsai CY; Yan SL
    Hematology; 2017 Dec; 22(10):592-598. PubMed ID: 28485688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reactivation of Hepatitis B Virus and Guidelines for Its Prevention].
    Tsubouchi H
    Rinsho Byori; 2015 Sep; 63(9):1046-51. PubMed ID: 26731892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Danish nationwide questionnaire study of hepatitis B virus screening before immunosuppressive therapy.
    Bunyoz KI; Krarup H; Weis N
    Dan Med J; 2017 Mar; 64(3):. PubMed ID: 28260595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of psoriasis patients with hepatitis B or hepatitis C virus infection.
    Bonifati C; Lora V; Graceffa D; Nosotti L
    World J Gastroenterol; 2016 Jul; 22(28):6444-55. PubMed ID: 27605880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection.
    Morisco F; Castiglione F; Rispo A; Stroffolini T; Sansone S; Vitale R; Guarino M; Biancone L; Caruso A; D'Inca R; Marmo R; Orlando A; Riegler G; Donnarumma L; Camera S; Zorzi F; Renna S; Bove V; Tontini G; Vecchi M; Caporaso N
    J Viral Hepat; 2013 Mar; 20(3):200-8. PubMed ID: 23383659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention.
    Sagnelli C; Pisaturo M; Calò F; Martini S; Sagnelli E; Coppola N
    World J Gastroenterol; 2019 Jul; 25(26):3299-3312. PubMed ID: 31341357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.